Retatrutide: what it is and what to check before buying

Retatrutide is a synthetic peptide, CAS 2381089-83-2, known in the published literature by the development code LY3437943. It holds no marketing authorisation in the United Kingdom or the European Union. Anything offered for sale under the name is an unapproved chemical, and three things can be checked before buying: identity, the analysis behind any figure quoted, and where that analysis came from.

Nomenclature: retatrutide, LY3437943, "triple agonist"

Three names attach to the same molecule and they do not promise the same things. Retatrutide is the International Nonproprietary Name, the name a compound is given so that everyone writing about it means the same thing. LY3437943 is the originator's development code, and it is the string to search for the primary literature, because work published before the INN settled uses the code and nothing else. Listings also write RETA, Reta or LY-3437943. Those are the same compound, and the CAS number is what confirms it.

The third term needs care. Retatrutide is described in the literature as a triple agonist: the published pharmacology reports activity at three receptors, GLP-1, GIP and glucagon. That is a classification of the molecule as studied, not a statement about a vial. Peptorium does not summarise what those studies found, does not carry any finding across to a person or an animal, and runs no clinical research. The distinction matters because a class name is the easiest thing in this trade to quote as though it were a result. It describes what a molecule binds in an assay. It says nothing at all about what is in the container in front of you.

Identity: formula, mass, and why the salt form changes the number

Retatrutide is a single-chain synthetic peptide, reported in the literature as a 39-residue chain carrying a fatty-acid modification, with CAS number 2381089-83-2. The public chemical record is worth opening rather than taking second hand: the entry for retatrutide (sodium salt) on PubChem, CID 171934787, gives the formula C₂₂₁H₃₄₂N₄₆O₆₈ for that form.

That entry is also a lesson in how mass figures drift. The sodium salt and the free acid are the same peptide with different counter-ions, and they do not weigh the same. The specification beside this text gives a theoretical mass of 4731.04 Da for the free acid. A supplier quoting a number some dozens of daltons away is not necessarily wrong, but is describing a different form and owes you the word for it. A listing that gives a name and no mass has identified nothing. A listing that gives a mass without saying whether it is the free acid, the acetate or the sodium salt has identified it approximately, and approximately is not what an identity check is for.

This is not a hypothetical failure mode. Two of the most-traded names in this category are ambiguous in exactly this way, and the ambiguity is worth more than a factor of five: TB-500 is sold both as full-length thymosin beta-4, around 4963 Da, and as a short fragment of around 889 Da, while CJC-1295 exists with and without a DAC complex, about 3647 g/mol against about 3368. Retatrutide is at least unambiguous in its name. Asking for the mass is how it stays that way.

Regulatory status in the UK and the European Union

Retatrutide has no marketing authorisation. It is not licensed as a medicine in the United Kingdom, it is not authorised centrally by the European Medicines Agency, and it sits on no national register in the EU. That can be checked at source rather than taken from a shop. The European Medicines Agency's medicines database lists what has been authorised in the EU, and the EMA's own account of the centralised and national authorisation routes explains what an authorisation is and how one is granted. A name absent from those records has been assessed by nobody.

In the UK the instrument is the Human Medicines Regulations 2012. Regulation 46 states that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product. Whether a given substance is a medicinal product at all is answered by regulation 2, which defines it in two limbs. A substance presented as having properties of preventing or treating disease is a medicinal product because of how it is presented. A substance that may be administered with a view to restoring, correcting or modifying a physiological function is one because of what it does. The first limb is the one that catches sellers: in law, a compound with no authorisation can be turned into an unauthorised medicine by nothing more than the sentence written beside it. That is one reason no sentence on this site describes an outcome in a person.

The compound is not abandoned science either, and pretending otherwise would be its own distortion. A phase 2 trial of LY3437943 was published in the New England Journal of Medicine in 2023 (PubMed 37366315), and the registered clinical programme can be read in full on ClinicalTrials.gov. Two things follow from that, and only two. The molecule is under active investigation by its originator. And none of that investigation says anything whatever about material bought from a research-chemical supplier, which is not the same material, was not made under the same conditions, and has no chain of custody joining it to any of those studies. Sellers borrow the credibility of that programme constantly. It is not theirs to lend.

What "research use only" is, and what it is not

"Research use only" is a statement of intended purpose by a seller. It is not a category in UK or EU law, it is not a licence, and no authority reviews anything in order for the phrase to be printed. What it does is declare that the material is not offered as something to be used in people, which keeps the presentation limb of the medicinal-product definition out of play. What it does not do is make a substance safe, checked, or lawful to administer.

The phrase is not a purity claim, a quality claim or a manufacturing claim either, and it is regularly waved about as though it were all three. Where a page uses it in place of saying who made the material and what was measured, it is doing the opposite of what it appears to do.

Purity and peptide content are two different numbers

This is the most useful thing a buyer of any peptide can learn, and it is why most listings look better than they are.

Purity by HPLC is a ratio. A sample is separated on a column, every peak is integrated, and the purity figure is the area of the main peak as a share of all the peak area detected. It answers one question: of the peptide material the method saw, how much was the target? A figure of 99% means the intended compound accounted for 99% of what the column separated.

Peptide content is a quantity. It is the share of the mass in the vial that is peptide at all. The remainder is residual water and the counter-ions left behind by synthesis and freeze-drying, usually acetate or trifluoroacetate. For a lyophilised peptide it commonly sits well below the purity figure, and that is ordinary rather than sinister - but it means a vial can be honestly described as high purity while holding appreciably less peptide than the label mass suggests. Neither number can be derived from the other. A certificate states both, and a seller quoting only the first has answered the easier question.

There is a fuller treatment in the guide on purity and peptide content and in the one on how to read a certificate of analysis.

Why the mass figure catches what purity cannot

Purity tells you how much of one thing is in the vial. Mass tells you which thing it is. A sample can be 99% one compound and still be 99% the wrong compound, and only the mass spectrometry result catches that. On a certificate worth reading, the measured mass sits beside the mass calculated from the sequence, and the two agree to within the resolution of the instrument. That is the identity check, and it is the figure to read first - ahead of the headline percentage, which is the figure designed to be read first.

The impurity peaks matter as much as the headline. A batch reported at a given purity with one large impurity is not the same material as a batch reported at the same purity with four small ones, and a report listing only the main peak has not shown you which you have. For a peptide of this length the plausible impurities are deletion sequences - chains missing a residue - and they are close enough in mass to the target that a report with no chromatogram is not telling you very much.

What Peptorium publishes about this material

This page publishes identity: the sequence, the molecular formula and CAS 2381089-83-2. Each of those can be checked against a public register rather than taken on trust. Purity, peptide content and water describe one batch rather than a compound. Those figures belong on a certificate of analysis issued by the laboratory that tested that batch, and they travel with the material itself.

What to ask before buying retatrutide from anyone

• What is the batch number, and is there a certificate for that batch, rather than one certificate reused across every vial of the product?
• Does the certificate state a measured mass beside the theoretical mass, or only a purity percentage?
• Which form does the mass refer to - free acid, acetate, sodium salt? A figure without a form is not an identity.
• Are the individual impurity peaks listed, or only the headline figure? Is there a chromatogram at all?
• Is peptide content stated separately from purity, and is water content given by Karl Fischer titration?
• Are the method and the test date named? A result with no method is not a result, and a certificate with no date belongs to no batch.
• Can the finding be checked with the laboratory that produced it, under that laboratory's own report number, somewhere the seller does not control? A PDF on a seller's own site is a document, and documents are editable.
• Who is the seller in the legal sense - a registered company, in a named jurisdiction, with an address that exists? This question sorts more suppliers than any of the analytical ones.

What is not known

• What any particular vial contains cannot be known without analysing it. Not from this page, not from a listing, and not from a certificate that cannot be tied to the vial by a batch number printed on the label.
• The published clinical work concerns material made by its originator under conditions no research-chemical supplier can evidence. Its results do not transfer to anything bought elsewhere, and this page draws no conclusion from them.
• Long-term stability of a lyophilisate outside the stated storage conditions has no reliable general answer. What is written about storage is convention, not measurement.
• Sport and competition rules are a separate regime with their own lists, and they change independently of medicines law. Anyone subject to them checks with their own federation, not with a shop.

Frequently asked questions

A lyophilisate is reconstituted with bacteriostatic water, and the volume of solvent chosen is what sets the concentration of the resulting solution; the peptide calculator converts between vial content, solvent volume and concentration. No quantity is recommended here and none is implied. Material described on this site is for laboratory and in vitro research use: it is not a medicine, not a food supplement and not a medical device, and the research declaration sets out what that means.